FilingReader Intelligence
Astellas' PADCEV improves bladder cancer survival in trial
August 12, 2025 at 10:02 AM UTC•By FilingReader AI
The EV-303 trial demonstrated statistically significant improvements in event-free survival and overall survival for patients receiving PADCEV with KEYTRUDA versus surgery alone. This is the only regimen to show improved survival for cisplatin-ineligible muscle-invasive bladder cancer patients.
Astellas Pharma and Pfizer will discuss results with regulatory authorities for potential filings.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
TSE:4503•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Astellas Pharma publishes news
Free account required • Unsubscribe anytime